Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1

Journal of Medical Genetics

Volumn 44, Issue 7, 2007, Pages 463-466

  McCaughan, J A ^a   Holloway, S M ^a   Davidson, R ^b   Lam, W W K ^a,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Yorkhill Hospitals   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PATIENT EDUCATION; PRIORITY JOURNAL; UNITED KINGDOM;

HUMANS; INCIDENCE; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; RISK ASSESSMENT; SCOTLAND; SURVIVAL ANALYSIS;

EID: 34447328730     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.048140     Document Type: Article

References (16)

1. Huson SM, Compston DAS, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26:704-11.
2. Diagnostic criteria for neurofibromatosis type 1 from the 1987 NIH Consensus Development Conference Statement on Neurofibromatosis.
3. Zöller ME, Rembeck B, Odén A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125.
4. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis survival and malignant neoplasms. N Engl J Med 1986;314:1010-15.
5. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981;305:1617-27.
6. Wanebo J, Malik J, VandenBerg S, Wanebo H, Driessen N, Persing J. Malignant peripheral nerve sheath tumors: a clinicopathological study of 28 cases. Cancer 1993;71:1247-53.
7. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-14.
8. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-21.
9. Bundey S. Phacomatoses and tumours. In: Emery AEH, eds. Genetics and neurology.2nd edn. Edinburgh: Churchill Livingstone, 1992:37-66.
10. Zöller M, Rembeck B, Åkesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1: a twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Dermatol Venereol 1995;75:136-40.
11. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 2001;68:1110-18.
12. Gosh BC, Gosh L, Huvos AG. Malignant schwannoma; a clinicopathological study. Cancer 1973;31:184-90.
13. Dasgupta TK, Brasfield RD. Solitary malignant schwannoma. Ann Surg 1970;171:419-28.
14. De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003;72:1288-92.
15. Ferner RE, Hughes RAC, Hall SM, Upadhyaya M, Johnson MR. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet 2004;41:837-41.
16. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005;65:205-11.